{
      "Rank": 289,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "\"ex-vivo\" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue (under Xcelia-GMP conditions)for osteonecrosis of the femoral head",
            "Isolated core decompression"
      ],
      "ArmGroupInterventionName": [
            "Biological: XCEL-MT-OSTEO-ALPHA",
            "Procedure: Standard treatment"
      ],
      "ArmGroupLabel": [
            "XCEL-MT-OSTEO-ALPHA",
            "Standard Treatment"
      ],
      "ArmGroupType": [
            "Experimental",
            "Sham Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT01605383"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The present study evaluates the effect of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral head in comparison to the standard treatment of isolated core decompression.\n\nXCEL-MT-OSTEO-ALPHA is a tissue engineering product composed by \"ex-vivo\" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue.\n\nThe working hypothesis proposes that the tissue engineering is a valid and useful technique to achieve bone regeneration, avoiding the progression to collapse of the femoral head."
      ],
      "BriefTitle": [
            "Mesenchymal Stem Cells in Osteonecrosis of the Femoral Head"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [
            "OTHER_GOV",
            "OTHER_GOV",
            "OTHER"
      ],
      "CollaboratorName": [
            "Ministerio de Sanidad, Servicios Sociales e Igualdad",
            "Ministerio de Ciencia e Innovaci\u00f3n, Spain",
            "European Regional Development Fund"
      ],
      "CompletionDate": [
            "June 27, 2019"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Avascular Necrosis of Femur Head"
      ],
      "ConditionAncestorId": [
            "D000010335",
            "D000001847",
            "D000009140"
      ],
      "ConditionAncestorTerm": [
            "Pathologic Processes",
            "Bone Diseases",
            "Musculoskeletal Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC23",
            "All",
            "BC05",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Symptoms and General Pathology",
            "All Conditions",
            "Musculoskeletal Diseases",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Necrosis",
            "Osteonecrosis",
            "Osteonecrosis of the Femoral Head",
            "Avascular Necrosis of Femur Head",
            "Osteonecrosis of the Femoral Head"
      ],
      "ConditionBrowseLeafId": [
            "M11436",
            "M11249",
            "M4278",
            "M12095",
            "M10037",
            "M7561",
            "T3358"
      ],
      "ConditionBrowseLeafName": [
            "Necrosis",
            "Musculoskeletal Diseases",
            "Bone Diseases",
            "Osteonecrosis",
            "Legg-Calve-Perthes Disease",
            "Femur Head Necrosis",
            "Legg-Calve-Perthes Disease"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "low",
            "high",
            "high",
            "high",
            "high"
      ],
      "ConditionMeshId": [
            "D000010020",
            "D000007873",
            "D000005271",
            "D000009336"
      ],
      "ConditionMeshTerm": [
            "Osteonecrosis",
            "Legg-Calve-Perthes Disease",
            "Femur Head Necrosis",
            "Necrosis"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "None (Open Label)"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "Prospective, open-label with blinded assessor, randomized, parallel, single-dose phase I-II clinical trial in which 24 patients affected with osteonecrosis of the femoral head ARCO grade I or II will enter the trial with the primary objective of assessing the feasibility and safety of \"ex-vivo\" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in osteonecrosis of the femoral head. Secondary objectives are to assess the efficacy of the implantation by imaging (magnetic resonance imaging) and clinical questionnaires (pain by visual analogue scale, quality of life by SF-36 and WOMAC Index).\n\nPatients will be randomized to one of the two treatment arms (core decompression and the tissue engineering product composed by \"ex-vivo\" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue or the standard treatment of isolated core decompression). Thereafter, patients will be followed for 12 months."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\n18 to 50 years of age (male and female)\nOsteonecrosis of the hip ARCO grade I or II\nAbscence of systemic or local infection\nLaboratory tests with no relevant abnormal findings that contraindicate the surgery.\nInformed Consent Form signed\nThe patient is able to understand the nature of the study\n\nExclusion Criteria:\n\nOsteonecrosis of the hip secondary to femoral neck fracture\nPatients with no closed cartilage\nSurgical implants in the femoral head\nSeptic arthritis\nPatients with severe renal insufficiency\nPatients expecting or with liver transplantation\nPositive serology for HIV-1 or HIV-2, Hepatitis B (HBsAg), Hepatitis C (Anti-HCV-Ab) or Syphilis.\nPregnant woman or intended to become pregnant, or breath feeding\nNeoplasia within the previous 5 years, or without remission\nImmunosuppressive states\nThe patient is legally dependent\nParticipation in another clinical trial or treated with an investigational medicinal product the previous 30 days\nCardiac pacemaker, allergy to contrast or any other condition that contraindicates the MRI with contrast agents\nOther pathologic conditions or circumstances that difficult participation in the study according to medical criteria\nThe patient does not accept to be followed-up for a period thar could exceed the clinical trial length"
      ],
      "EnrollmentCount": [
            "23"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "XCEL-MT-OSTEO-ALPHA",
            "Standard Treatment"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "Core decompression plus XCEL-MT-OSTEO-ALPHA",
            "Isolated core decompression"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "XCEL-MT-OSTEO-ALPHA",
            "Standard treatment"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological",
            "Procedure"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "Avascular Necrosis of Femur Head",
            "Osteonecrosis of the hip",
            "Osteonecrosis of the femoral head",
            "Mesenchymal Stem Cells",
            "Bone marrow",
            "Tissue engineering",
            "Bone Diseases",
            "Musculoskeletal Diseases"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "January 21, 2020"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "January 15, 2020"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Banc de Sang i Teixits"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Barcelona"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "Spain"
      ],
      "LocationFacility": [
            "Hospital Universitari Vall d'Hebron"
      ],
      "LocationState": [],
      "LocationStatus": [],
      "LocationZip": [
            "08035"
      ],
      "MaximumAge": [
            "50 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "A Pilot Clinical Trial of \"ex Vivo\" Expanded Autologous Bone Marrow Mesenchymal Stem Cells Fixed in Allogenic Human Bone Tissue (XCEL-MT-OSTEO- ALPHA) in Osteonecrosis of the Femoral Head"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Banc de Sang i Teixits"
      ],
      "OrgStudyId": [
            "XCEL-MT-10-01"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Hospital Vall d'Hebron"
      ],
      "OverallOfficialName": [
            "M\u00e0rius Aguirre, MD, PhD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "No"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "April 11, 2018"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [
            "Safety will be assessed by collecting adverse events throughout the experimental phase, which includes a follow-up of 12 months",
            "Feasibility will be measured by assessing the percentage of patients to which bone marrow puncture is made are thereafter treated and by checking the cascade of procedures to confirm the global process is viable."
      ],
      "PrimaryOutcomeMeasure": [
            "Safety of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral head",
            "Feasibility of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral head"
      ],
      "PrimaryOutcomeTimeFrame": [
            "12 months",
            "12 months"
      ],
      "ReferenceCitation": [
            "Vives J, Oliver-Vila I, Pla A. Quality compliance in the shift from cell transplantation to cell therapy in non-pharma environments. Cytotherapy. 2015 Aug;17(8):1009-14. doi: 10.1016/j.jcyt.2015.02.002. Epub 2015 Mar 10. Review."
      ],
      "ReferencePMID": [
            "25769789"
      ],
      "ReferenceType": [
            "derived"
      ],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [
            "2010-023998-18"
      ],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [
            "EudraCT Number"
      ],
      "SecondaryOutcomeDescription": [
            "The necrotic angle will be measured using imaging procedures (magnetic resonance imaging MRI).",
            "Dynamic changes of signal intensity after Gd enhancement in the necrotic areas of the femoral head",
            "Pain measurement by VAS",
            "This clinical outcome will measure the quality of life by the self-reported quality of life questionnaire SF-36",
            "To assess the extent by which a person's functional level is restricted by the WOMAC index"
      ],
      "SecondaryOutcomeMeasure": [
            "Bone regeneration by measuring the necrotic angle using the modified Kerboul method",
            "Dynamic changes of signal intensity",
            "Clinical outcomes (pain) by Visual Analogue Scale (VAS)",
            "Clinical outcomes (SF-36)",
            "Clinical outcome (WOMAC)"
      ],
      "SecondaryOutcomeTimeFrame": [
            "6 and 12 months",
            "6 and 12 months",
            "7 days and at 3, 6 and 12 months",
            "3, 6 and 12 months",
            "3, 6 and 12 months"
      ],
      "SeeAlsoLinkLabel": [
            "Banc de Sang i Teixits. Xcelia-Divisi\u00f3n de Terapias Avanzadas.",
            "Hospital Universitari Vall d'Hebron, Barcelona"
      ],
      "SeeAlsoLinkURL": [
            "http://www.bancsang.net/",
            "http://www.vhebron.net/"
      ],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "May 5, 2015"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "January 2020"
      ],
      "StdAge": [
            "Adult"
      ],
      "StudyFirstPostDate": [
            "May 24, 2012"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "May 22, 2012"
      ],
      "StudyFirstSubmitQCDate": [
            "May 23, 2012"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}